Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 13/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | ESR1 | P03372 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | SHBG | P04278 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16000745 | 0.89 | ESR2 (0.54) | ESR2ACHEKDM1AESR1CYP3A4 | |
| SCHEMBL18559749 | 0.78 | KDM1A (0.54) | ESR2ACHEKDM1AESR1CYP3A4 | |
| SCHEMBL18559915 | 0.78 | KDM1A (0.54) | ESR2ACHEKDM1AESR1CYP3A4 | |
| SCHEMBL28189819 | 0.76 | ACHE (0.55) | ESR2ACHEKDM1AESR1CYP3A4 | |
| SCHEMBL10884060 | 0.76 | ESR2 (0.55) | ESR2ACHEKDM1AESR1CYP3A4 | |
| SCHEMBL27745696 | 0.76 | ESR2 (0.55) | ESR2ACHEKDM1AESR1CYP3A4 | |
| Ammonia Solution, Strong SCHEMBL268752 | 0.76 | KDM1A (0.52) | ESR2ACHEKDM1AESR1CYP3A4 | |
| SCHEMBL9861182 | 0.75 | ESR2 (0.48) | ESR2ACHEKDM1AESR1CYP3A4 | |
| SCHEMBL27991642 | 0.73 | ESR2 (0.40) | ESR2KDM1AESR1CYP3A4CYP2C9 | |
| SCHEMBL13484238 | 0.71 | ESR2 (0.44) | ESR2ACHEKDM1AESR1SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170369437-A1 | Process for Preparing Alpha-Carboxamide Pyrrolidine Derivatives | Convergence Pharmaceuticals Limited (GB) | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369437-A1 | Process for Preparing Alpha-Carboxamide Pyrrolidine Derivatives | CPS1, ALDH18A1, PCCA | ESR2 4309/4885ACHE 985/4885KDM1A 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.